{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:51:29Z","timestamp":1794243089012,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Capital Fund for Health Improvement and Research","award":["2016-2-4021"],"award-info":[{"award-number":["2016-2-4021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Preoperative chemoradiotherapy (CRT) followed by surgery is the most common approach for patients with resectable esophageal cancer. Nevertheless, considerable numbers of esophageal-cancer patients undergo surgery as the first treatment. The benefit of neoadjuvant therapy might only be for patients with a pathologic complete response, so stratified research is necessary. Postoperative treatments have important roles because of the poor survival rates of patients with stage-IIB\/III disease treated with resection alone. Five-year survival of patients with stage-IIB\/III thoracic esophageal squamous cell carcinoma (TESCC) after surgery is 20.0\u201328.4%, and locoregional lymph-node metastases are the main cause of failure. Several retrospective studies have shown that postoperative radiotherapy (PORT) and postoperative chemoradiotherapy (POCRT) after radical esophagectomy for esophageal carcinoma with positive lymph-node metastases and stage-III disease can decrease locoregional recurrence and increase overall survival (OS). Using intensity-modulated RT, PORT reduces locoregional recurrence further. However, the rate of distant metastases increases to 30.7%. Hence, chemotherapy may be vital for these patients. Therefore, a prospective randomized controlled trial (RCT) is needed to evaluate the value of PORT and concurrent POCRT in comparison with surgery alone (SA) for esophageal cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This will be a phase-II\/III RCT. The patients with pathologic stage-IIB\/III esophageal squamous cell carcinoma will receive concurrent POCRT or PORT after radical esophagectomy compared with those who have SA. A total of 120 patients in each group will be recruited. POCRT patients will be 50.4\u2009Gy concurrent with paclitaxel (135\u2013150\u2009mg\/m<jats:sup>2<\/jats:sup>) plus cisplatin or nedaplatin (50\u201375\u2009mg\/m<jats:sup>2<\/jats:sup>) treatment every 28\u2009days. Two cycles will be required for concurrent chemotherapy. The prescription dose will be 54\u2009Gy for PORT. The primary endpoint will be disease-free survival (DFS). The secondary endpoint will be OS. Other pre-specified outcome measures will be the proportion of patients who complete treatment, toxicity, and out-of-field regional recurrence rate between PORT and POCRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This prospective RCT will provide high-level evidence for postoperative adjuvant treatment of pathologic stage-IIB\/III esophageal squamous cell carcinoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>clinicaltrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/register.clinicaltrials.gov\/\">NCT02279134<\/jats:ext-link>). Registered on October 26, 2014.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-6592-2","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T09:02:54Z","timestamp":1582016574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A phase-II\/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB\/III esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Wenjie","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-6814","authenticated-orcid":false,"given":"Zefen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jima","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"6592_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332.","journal-title":"CA Cancer J Clin"},{"key":"6592_CR2","first-page":"549","volume":"25","author":"J Lu","year":"2013","unstructured":"Lu J, Tao H, Song D, Chen C. Recurrence risk model for esophageal cancer after radical surgery. Chin J Cancer Res. 2013;25:549\u201355.","journal-title":"Chin J Cancer Res"},{"key":"6592_CR3","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1245\/s10434-011-1747-7","volume":"18","author":"H Miyata","year":"2011","unstructured":"Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M, Doki Y. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:3353\u201361.","journal-title":"Ann Surg Oncol"},{"key":"6592_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.2013.51.2186","volume":"32","author":"V Oppedijk","year":"2014","unstructured":"Oppedijk V, van der Gaast A, van Lanschot JJB, van Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative Chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385\u201391.","journal-title":"J Clin Oncol"},{"key":"6592_CR5","doi-asserted-by":"publisher","first-page":"e97225","DOI":"10.1371\/journal.pone.0097225","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Cai XW, Wu B, Zhu ZF, Chen HQ, Fu XL. Patterns of failure after radical surgery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy. PLoS One. 2014;9:e97225.","journal-title":"PLoS One"},{"key":"6592_CR6","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11605-011-1458-1","volume":"15","author":"PK Hsu","year":"2011","unstructured":"Hsu PK, Wang BY, Huang CS, Wu YC, Hsu WH. Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection. J Gastrointest Surg. 2011;15:558\u201365.","journal-title":"J Gastrointest Surg"},{"key":"6592_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3892\/ol.2012.946","volume":"5","author":"CL Li","year":"2013","unstructured":"Li CL, Zhang FL, Wang YD, Han C, Sun GG, Liu Q, Cheng YJ, Jing SW, Yang CR. Characteristics of recurrence after radical esophagectomy with two-field lymph node dissection for thoracic esophageal cancer. Oncol Lett. 2013;5:355\u20139.","journal-title":"Oncol Lett"},{"key":"6592_CR8","first-page":"949","volume":"6","author":"XD Su","year":"2014","unstructured":"Su XD, Zhang DK, Zhang X, Lin P, Long H, Rong TH. Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma. J Thorac Dis. 2014;6:949\u201357.","journal-title":"J Thorac Dis"},{"key":"6592_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2214\/ajr.105.3.523","volume":"105","author":"JT Goodner","year":"1969","unstructured":"Goodner JT. Surgical and radiation treatment of cancer of the thoracic esophagus. Am J Roentgenol Radium Therapy, Nucl Med. 1969;105:523\u20138.","journal-title":"Am J Roentgenol Radium Therapy, Nucl Med"},{"key":"6592_CR10","first-page":"123","volume":"173","author":"P Teniere","year":"1991","unstructured":"Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University association for surgical research. Surg Gynecol Obstet. 1991;173:123\u201330.","journal-title":"Surg Gynecol Obstet"},{"key":"6592_CR11","first-page":"138","volume":"113","author":"M Fok","year":"1993","unstructured":"Fok M, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery. 1993;113:138\u201347.","journal-title":"Surgery."},{"key":"6592_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/BF00299187","volume":"19","author":"HU Zieren","year":"1995","unstructured":"Zieren HU, Muller JM, Jacobi CA, Pichlmaier H, Muller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995;19:444\u20139.","journal-title":"World J Surg"},{"key":"6592_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0003-4975(02)04401-6","volume":"75","author":"ZF Xiao","year":"2003","unstructured":"Xiao ZF, Yang ZY, Liang J, Miao YJ, Wang M, Yin WB, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. Ann Thorac Surg. 2003;75:331\u20136.","journal-title":"Ann Thorac Surg"},{"key":"6592_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1055\/s-2008-1069212","volume":"109","author":"U Kunath","year":"1984","unstructured":"Kunath U, Fischer P. Radical nature and life expectancy in the surgical treatment of esophageal and cardial carcinoma. Dtsch Med Wochenschr. 1984;109:450\u20133.","journal-title":"Dtsch Med Wochenschr"},{"key":"6592_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e3181c5e34f","volume":"5","author":"D Schreiber","year":"2010","unstructured":"Schreiber D, Rineer J, Vongtama D, Wortham A, Han P, Schwartz D, Choi K, Rotman M. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244\u201350.","journal-title":"J Thorac Oncol"},{"key":"6592_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jamcollsurg.2012.07.006","volume":"215","author":"M Worni","year":"2012","unstructured":"Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012;215:643\u201351.","journal-title":"J Am Coll Surg"},{"key":"6592_CR17","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s11605-013-2192-7","volume":"17","author":"R Shridhar","year":"2013","unstructured":"Shridhar R, Weber J, Hoffe SE, Almhanna K, Karl R, Meredith K. Adjuvant radiation therapy and lymphadenectomy in esophageal Cancer: a SEER database analysis. J Gastrointest Surg. 2013;17:1339\u201345.","journal-title":"J Gastrointest Surg"},{"key":"6592_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ijrobp.2010.08.037","volume":"82","author":"J Chen","year":"2012","unstructured":"Chen J, Pan J, Zheng X, Zhu K, Li J, Chen M, Wang J, Liao Z. Number and location of positive nodes, postoperative radiotherapy, and survival after Esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma. Int J Radiation Oncology Biol Phys. 2012;82:475\u201382.","journal-title":"Int J Radiation Oncology Biol Phys."},{"key":"6592_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1748-717X-8-116","volume":"8","author":"Y Xu","year":"2013","unstructured":"Xu Y, Liu J, Du X, Sun X, Zheng Y, Chen J, et al. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol. 2013;8:116.","journal-title":"Radiat Oncol"},{"key":"6592_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375391","volume":"38","author":"W Zhang","year":"2015","unstructured":"Zhang W, Liu X, Xiao Z, Zhang H, Chen D, Feng Q, et al. Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell Carcinoma. Oncol Res Treat. 2015;38:97\u2013102.","journal-title":"Oncol Res Treat"},{"key":"6592_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ijrobp.2013.03.026","volume":"86","author":"J Chen","year":"2013","unstructured":"Chen J, Pan J, Liu J, Li J, Zhu K, Zheng X, Chen M, Chen M, Liao Z. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma. Int J Radiation Oncology Biol Phys. 2013;86:671\u20137.","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"6592_CR22","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.athoracsur.2013.12.041","volume":"97","author":"P Hsu","year":"2014","unstructured":"Hsu P, Huang C, Wang B, Wu Y, Hsu W. Survival benefits of postoperative Chemoradiation for lymph node\u2013positive esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;97:1734\u201341.","journal-title":"Ann Thorac Surg"},{"key":"6592_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2019.06.020","volume":"140","author":"S Yu","year":"2019","unstructured":"Yu S, Zhang W, Ni W, Xiao Z, Wang Q, Zhou Z, et al. A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. Radiother Oncol. 2019;140:159\u201366.","journal-title":"Radiother Oncol"},{"key":"6592_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1442-2050.2008.00901.x","volume":"22","author":"TW Rice","year":"2009","unstructured":"Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1\u20138.","journal-title":"Dis Esophagus"},{"key":"6592_CR25","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1245\/s10434-013-2936-3","volume":"20","author":"RL Blom","year":"2013","unstructured":"Blom RL, Lagarde SM, van Oudenaarde K, Klinkenbijl JHG, Hulshof MC, van Laarhoven HW, Bergman JJ, Busch OR, van Berge Henegouwen MI. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann Surg Oncol. 2013;20:2693\u20138.","journal-title":"Ann Surg Oncol"},{"key":"6592_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13019-014-0150-4","volume":"9","author":"XF Guo","year":"2014","unstructured":"Guo XF, Mao T, Gu ZT, Ji CY, Fang WT, Chen WH. Clinical study on postoperative recurrence in patients with pN0 esophageal squamous cell carcinoma. J Cardiothorac Surg. 2014;9:150.","journal-title":"J Cardiothorac Surg"},{"key":"6592_CR27","first-page":"2423","volume":"91","author":"EL Bedard","year":"2001","unstructured":"Bedard EL, Inculet RI, Malthaner RA, Brecevic E, Vincent M, Dar R. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer-Am Cancer Soc. 2001;91:2423\u201330.","journal-title":"Cancer-Am Cancer Soc."},{"key":"6592_CR28","first-page":"379","volume":"05","author":"XY Qiao","year":"2006","unstructured":"Qiao XY, Zhou DA, Lin Q, Gao XS, Zhou ZG, Wang W, et al. Portal size of prophylactic postoperative radiotherapy for esophageal carcinoma. Chin J Radiat Oncol. 2006;05:379\u201382.","journal-title":"Chin J Radiat Oncol."},{"key":"6592_CR29","first-page":"374","volume":"26","author":"JQ Chen","year":"2006","unstructured":"Chen JQ, Chen MQ, Li YY, Pan JJ, Wu JX, Xu ZL, et al. Clinical study on the target of prophylactic radiotherapy sifter three field radical esophagectomy of thoracic esophageal carcinoma. Chin J Radiol Med Prot. 2006;26:374\u20137.","journal-title":"Chin J Radiol Med Prot"},{"key":"6592_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijrobp.2004.08.046","volume":"62","author":"Z Xiao","year":"2005","unstructured":"Xiao Z, Yang Z, Miao Y, Wang L, Yin W, Gu X, et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases. Int J Radiation Oncol Biol Phys. 2005;62:82\u201390.","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"6592_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa010187","volume":"345","author":"JS Macdonald","year":"2001","unstructured":"Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725\u201330.","journal-title":"N Engl J Med"},{"key":"6592_CR32","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0022-5223(03)01025-0","volume":"126","author":"TW Rice","year":"2003","unstructured":"Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC, Blackstone EH. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg. 2003;126:1590\u20136.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"6592_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/145749691210100106","volume":"101","author":"SC Kofoed","year":"2012","unstructured":"Kofoed SC, Muhic A, Baeksgaard L, Jendresen M, Gustafsen J, Holm J, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg. 2012;101:26\u201331.","journal-title":"Scand J Surg"},{"key":"6592_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2010.04.029","volume":"96","author":"W Cai","year":"2010","unstructured":"Cai W, Xin P. Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy. Radiother Oncol. 2010;96:104\u20137.","journal-title":"Radiother Oncol"},{"key":"6592_CR35","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/1759-7714.12499","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu J, Cai X, Liu Q, Li H, Cheng Y, Fu X. Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer. Thorac Cancer. 2017;8:630\u20133.","journal-title":"Thorac Cancer"},{"key":"6592_CR36","first-page":"e185424","volume":"12","author":"J Chen","year":"2017","unstructured":"Chen J, Cai W, Lin Y, Chen Y, Zheng Q, Pan J, Chen C. Patterns and rates of abdominal lymphatic metastasis following esophageal carcinoma. PLoS One. 2017;12:e185424.","journal-title":"PLoS One"},{"key":"6592_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.radonc.2004.08.024","volume":"73","author":"E Yu","year":"2004","unstructured":"Yu E, Dar R, Rodrigues GB, Stitt L, Videtic GM, Truong P, et al. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients? Radiother Oncol. 2004;73:141\u20138.","journal-title":"Radiother Oncol"},{"key":"6592_CR38","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1442-2050.2007.00797.x","volume":"21","author":"JC Lu","year":"2008","unstructured":"Lu JC, Tao H, Zhang YQ, Zha WW, Qian PD, Li F, Xu KX. Extent of prophylactic postoperative radiotherapy after radical surgery of thoracic esophageal squamous cell carcinoma. Dis Esophagus. 2008;21:502\u20137.","journal-title":"Dis Esophagus"},{"key":"6592_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3747\/co.v16i4.355","volume":"16","author":"E Yu","year":"2009","unstructured":"Yu E, Tai P, Younus J, Malthaner R, Truong P, Stitt L, et al. Postoperative extended-volume external-beam radiation therapy in high-risk esophageal cancer patients: a prospective experience. Curr Oncol. 2009;16:48\u201354.","journal-title":"Curr Oncol"},{"key":"6592_CR40","first-page":"1616","volume":"97","author":"C Mariette","year":"2003","unstructured":"Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer-Am Cancer Soc. 2003;97:1616\u201323.","journal-title":"Cancer-Am Cancer Soc"},{"key":"6592_CR41","first-page":"26","volume":"25","author":"SF Yu","year":"2016","unstructured":"Yu SF, Zhang WC, Wang QF, Xiao ZF, Zhou ZM, Feng QF, et al. Postoperative prophylactic concurrent radiochemotherapy for node-positive esophageal squamous cell carcinoma: a phase I clinical study. Chin J Radiat Oncol. 2016;25:26\u201331.","journal-title":"Chin J Radiat Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6592-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6592-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T07:25:09Z","timestamp":1613805909000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6592-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6592"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6592-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol has been approved by the ethics committee of the Chinese Academy of Medical Sciences (14\u2013090\/880). Written informed consent is obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}